These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 2875643)

  • 1. Drug interaction studies and encainide use in renal and hepatic impairment.
    Quart BD; Gallo DG; Sami MH; Wood AJ
    Am J Cardiol; 1986 Aug; 58(5):104C-113C. PubMed ID: 2875643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of the newer antiarrhythmic agents.
    Gillis AM; Kates RE
    Clin Pharmacokinet; 1984; 9(5):375-403. PubMed ID: 6437721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man.
    Barbey JT; Thompson KA; Echt DS; Woosley RL; Roden DM
    Circulation; 1988 Feb; 77(2):380-91. PubMed ID: 3123092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acute and long-term antiarrhythmia effect of encainide in chronic atrial extrasystole].
    Thale J; Klein H; Shanks RG; Bender F
    Z Kardiol; 1985 Apr; 74(4):220-7. PubMed ID: 2408392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of encainide and its major metabolites, O-demethyl encainide and 3-methoxy-O-demethyl encainide, on experimental cardiac arrhythmias in dogs.
    Kerr MJ; Allen JD; Harron DW; Shanks RG
    J Cardiovasc Pharmacol; 1985; 7(3):449-57. PubMed ID: 2410673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals.
    Carey EL; Duff HJ; Roden DM; Primm RK; Wilkinson GR; Wang T; Oates JA; Woosley RL
    J Clin Invest; 1984 Feb; 73(2):539-47. PubMed ID: 6421879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to encainide of refractory ventricular tachycardia: clinical application of assays for parent drug and metabolites.
    Anderson JL; Stewart JR; Johnson TA; Lutz JR; Pitt B
    J Cardiovasc Pharmacol; 1982; 4(5):812-9. PubMed ID: 6182414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition kinetics of encainide and metabolites.
    Roden DM; Wood AJ; Wilkinson GR; Woosley RL
    Am J Cardiol; 1986 Aug; 58(5):4C-9C. PubMed ID: 3092618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias.
    Winkle RA; Peters F; Kates RE; Tucker C; Harrison DC
    Circulation; 1981 Aug; 64(2):290-6. PubMed ID: 6788400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemodynamic effects of encainide in patients with ventricular arrhythmia and poor ventricular function.
    Sami MH; Derbekyan VA; Lisbona R
    Am J Cardiol; 1983 Sep; 52(5):507-11. PubMed ID: 6412535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias.
    Turgeon J; Pavlou HN; Wong W; Funck-Brentano C; Roden DM
    J Pharmacol Exp Ther; 1990 Nov; 255(2):642-9. PubMed ID: 2123007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of encainide and quinidine in the treatment of ventricular arrhythmias.
    Morganroth J; Somberg JC; Pool PE; Hsu PH; Lee IK; Durkee J; Salerno DM
    J Am Coll Cardiol; 1986 Jan; 7(1):9-16. PubMed ID: 3079781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of encainide.
    Roden DM; Woosley RL
    Clin Pharmacokinet; 1988 Mar; 14(3):141-7. PubMed ID: 3131058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and metabolism of encainide.
    Jaillon P
    Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():561-5. PubMed ID: 2125833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Encainide disposition in patients with renal failure.
    Bergstrand RH; Wang T; Roden DM; Stone WJ; Wolfenden HT; Woosley RL; Wilkinson GR; Wood AJ
    Clin Pharmacol Ther; 1986 Jul; 40(1):64-70. PubMed ID: 3087679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolite cumulation during long-term oral encainide administration.
    Kates RE; Harrison DC; Winkle RA
    Clin Pharmacol Ther; 1982 Apr; 31(4):427-32. PubMed ID: 6800679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myocardial uptake of encainide and its two major metabolites, O-demethyl encainide and 3-methoxy-O-demethyl encainide, in the dog.
    Latini R; Gillis AM; Kates RE
    J Cardiovasc Pharmacol; 1984; 6(4):663-7. PubMed ID: 6206322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation of blood level and metabolites to the antiarrhythmic effectiveness of encainide.
    Harrison DC; Kates RE; Quart BD
    Am J Cardiol; 1986 Aug; 58(5):66C-73C. PubMed ID: 3092622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total suppression of ventricular arrhythmias by encainide. Pharmacokinetic and electrocardiographic characteristics.
    Roden DM; Reele SB; Higgins SB; Mayol RF; Gammans RE; Oates JA; Woosley RL
    N Engl J Med; 1980 Apr; 302(16):877-82. PubMed ID: 6767186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative antiarrhythmic actions of encainide and its major metabolites.
    Gomoll AW; Byrne JE; Mayol RF
    Arch Int Pharmacodyn Ther; 1986 Jun; 281(2):277-97. PubMed ID: 3092755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.